NRG-GI011

Open to Accrual

Return to Protocol Table

A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Principal Investigator

Nina Sanford,

Status

Open to Accrual

Date Opened To Accrual

June 11 2025

Disease Site

Gastrointestinal [GI]

Other

Phase

III

Developmental Therapeutics

Primary Objective

To evaluate whether dose-escalated RT improves 3-year overall survival compared to standard treatments without dose-escalated RT, in locally advanced pancreatic cancer patients without radiographic progression and with biochemical response after an initial interval of chemotherapy.

Patient Population

Pathologically (histologically or cytologically) provendiagnosis of pancreatic ductal adenocarcinoma and locally advanced unresectabledisease as defined per the National Comprehensive Cancer Network guidelines andinstitutional tumor board review.

Target Accrual

356

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.